BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:BLC - FR0000035370 - Common Stock
26.15 EUR
-0.15 (-0.57%)
BLC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 27 industry peers in the Health Care Providers & Services industry. While BLC is still in line with the averages on profitability rating, there are concerns on its financial health. BLC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
BLC had positive earnings in the past year.
BLC had a positive operating cash flow in the past year.
BLC had positive earnings in 4 of the past 5 years.
Each year in the past 5 years BLC had a positive operating cash flow.
1.2 Ratios
The Return On Assets of BLC (0.08%) is worse than 81.48% of its industry peers.
With a Return On Equity value of 0.73%, BLC is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
Looking at the Return On Invested Capital, with a value of 6.40%, BLC is in line with its industry, outperforming 59.26% of the companies in the same industry.
BLC had an Average Return On Invested Capital over the past 3 years of 6.14%. This is in line with the industry average of 6.91%.
The 3 year average ROIC (6.14%) for BLC is below the current ROIC(6.40%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROIC | 6.4% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
The Profit Margin of BLC (0.11%) is worse than 81.48% of its industry peers.
In the last couple of years the Profit Margin of BLC has declined.
The Operating Margin of BLC (8.17%) is better than 62.96% of its industry peers.
In the last couple of years the Operating Margin of BLC has remained more or less at the same level.
BLC has a Gross Margin of 67.80%. This is amongst the best in the industry. BLC outperforms 81.48% of its industry peers.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BLC remains at a similar level compared to 1 year ago.
BLC has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for BLC has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.41, we must say that BLC is in the distress zone and has some risk of bankruptcy.
BLC has a worse Altman-Z score (1.41) than 66.67% of its industry peers.
BLC has a debt to FCF ratio of 12.90. This is a negative value and a sign of low solvency as BLC would need 12.90 years to pay back of all of its debts.
BLC has a Debt to FCF ratio of 12.90. This is comparable to the rest of the industry: BLC outperforms 40.74% of its industry peers.
BLC has a Debt/Equity ratio of 5.29. This is a high value indicating a heavy dependency on external financing.
BLC has a Debt to Equity ratio of 5.29. This is amonst the worse of the industry: BLC underperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.41 |
ROIC/WACC1.26
WACC5.08%
2.3 Liquidity
A Current Ratio of 1.38 indicates that BLC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.38, BLC is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BLC (1.18) is better than 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 158.33% over the past year.
Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
Looking at the last year, BLC shows a small growth in Revenue. The Revenue has grown by 6.35% in the last year.
Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
The Earnings Per Share is expected to grow by 15.96% on average over the next years. This is quite good.
BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3Y15.96%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.49%
Revenue Next 5Y7.69%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 373.57, BLC can be considered very expensive at the moment.
Based on the Price/Earnings ratio, BLC is valued more expensive than 81.48% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.31, BLC is valued quite expensively.
Based on the Price/Forward Earnings ratio of 9.57, the valuation of BLC can be described as reasonable.
BLC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 96.30% of the companies in the same industry.
BLC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 373.57 | ||
| Fwd PE | 9.57 |
4.2 Price Multiples
88.89% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BLC is valued cheaper than 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.05 | ||
| EV/EBITDA | 5.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as BLC's earnings are expected to grow with 15.96% in the coming years.
PEG (NY)8.98
PEG (5Y)N/A
EPS Next 2Y16.22%
EPS Next 3Y15.96%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (11/28/2025, 7:00:00 PM)
26.15
-0.15 (-0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap192.73M
Revenue(TTM)491.18M
Net Income(TTM)528.00K
Analysts83.33
Price Target36.72 (40.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP107.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.84%
EPS NY rev (3m)-8.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)2%
Revenue NY rev (3m)-14.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 373.57 | ||
| Fwd PE | 9.57 | ||
| P/S | 0.39 | ||
| P/FCF | 6.05 | ||
| P/OCF | 2.1 | ||
| P/B | 2.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.75 |
EPS(TTM)0.07
EY0.27%
EPS(NY)2.73
Fwd EY10.45%
FCF(TTM)4.32
FCFY16.54%
OCF(TTM)12.48
OCFY47.71%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)8.98
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.73% | ||
| ROCE | 8.71% | ||
| ROIC | 6.4% | ||
| ROICexc | 6.78% | ||
| ROICexgc | 12.12% | ||
| OM | 8.17% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.79 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.25% | ||
| Profit Quality | 6036.93% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.41 |
F-Score8
WACC5.08%
ROIC/WACC1.26
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y41.62%
EPS Next 2Y16.22%
EPS Next 3Y15.96%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.49%
Revenue Next 5Y7.69%
EBIT growth 1Y18.25%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year133.33%
EBIT Next 3Y39.49%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
What is the valuation status for BLC stock?
ChartMill assigns a valuation rating of 5 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the valuation of BASTIDE LE CONFORT MEDICAL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BASTIDE LE CONFORT MEDICAL (BLC.PA) is 373.57 and the Price/Book (PB) ratio is 2.67.
How sustainable is the dividend of BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 107.77%.